Virica Biotech, Inc.
Virica Biotech is dedicated to improving manufacturing productivity and reducing costs in cell and gene therapies and vaccine production by addressing cellular defenses with innovative solutions. They develop Viral Sensitizers (VSE™), a library of small molecule cell enhancers that increase viral yields, quality, and scalability, enabling more accessible and cost-effective therapies.
Industries
Nr. of Employees
small (1-50)
Products
Small-molecule viral sensitizer reagents
Reagent library of small molecules formulated to transiently antagonize cellular innate immunity during viral vector or vaccine production to increase yield and improve quality attributes.
Small-molecule viral sensitizer reagents
Reagent library of small molecules formulated to transiently antagonize cellular innate immunity during viral vector or vaccine production to increase yield and improve quality attributes.
Services
Provision of reagent kits composed of small-molecule enhancers intended to be added to viral production processes to boost yield and quality.
Rapid screening campaigns using high-throughput virology methods to identify application-specific small-molecule enhancers and candidate combinations.
Technical collaboration to integrate enhancers into existing cell lines and production workflows, including DoE-based optimization and bioreactor integration.
Cost and dose-sparing analyses that quantify potential manufacturing savings from yield improvements and reduced vector dose requirements.
Provision of reagent kits composed of small-molecule enhancers intended to be added to viral production processes to boost yield and quality.
Rapid screening campaigns using high-throughput virology methods to identify application-specific small-molecule enhancers and candidate combinations.
Technical collaboration to integrate enhancers into existing cell lines and production workflows, including DoE-based optimization and bioreactor integration.
Cost and dose-sparing analyses that quantify potential manufacturing savings from yield improvements and reduced vector dose requirements.
Expertise Areas
- Viral vector manufacturing optimization
- Small-molecule enhancer discovery
- High-throughput virology screening
- Design of Experiments (DoE) for bioprocessing
Key Technologies
- High-throughput screening (HTS) for virology
- Design of Experiments (DoE)
- Cloud-connected bioreactor integration
- Process automation for bioprocessing
News & Updates
Virica participated in the BIO International Convention from June 13 to June 16, 2022, at the San Diego Convention Center.
An update on industry insights published in April 2025.
An update on industry insights published in January 2025.
An update on industry insights published in October 2024.
Virica participated in the BIO International Convention from June 13 to June 16, 2022, at the San Diego Convention Center.
An update on industry insights published in April 2025.
An update on industry insights published in January 2025.
An update on industry insights published in October 2024.